Cytosorbents Corporation (CTSO)

Market Cap	149.44M
Revenue (ttm)	35.45M
Net Income (ttm)	-31.17M
Shares Out	43.95M
EPS (ttm)	-0.71
PE Ratio	n/a
Forward PE	106.38
Dividend	n/a
Ex-Dividend Date	n/a

Volume	65,224
Open	3.38
Previous Close	3.31
Day's Range	3.36 - 3.50
52-Week Range	1.03 - 4.59
Beta	0.75
Analysts	Strong Buy
Price Target	5.50 (+61.77%)
Earnings Date	Aug 1, 2023

About CTSO

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology. Its flagship product is CytoSorb, an extracorporeal cytokine filter for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention and treatment of perioperative complications of cardiopulmonary bypass surgery, and maintaining or enhancing the quality of solid organs harves...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 1997
• Employees: 198
• Stock Exchange: NASDAQ
• Ticker Symbol: CTSO

Financial Performance

In 2022, CytoSorbents's revenue was $34.69 million, a decrease of -19.64% compared to the previous year's $43.17 million. Losses were -$32.81 million, 33.6% more than in 2021.

Analyst Forecast

According to one analyst, the rating for CTSO stock is "Strong Buy" and the 12-month stock price forecast is $5.5.

Price Target

$5.5

(61.77% upside)

Analyst Consensus: Strong Buy